The objective of this study was to evaluate the effect of the CYP3A5*3 allele on the pharmacokinetics of tacrolimus and amlodipine, and drug-drug interactions between them in healthy subjects. Pharmacokinetic drug interactions between tacrolimus and amlodipine were evaluated in a randomized, 3-period, 6-sequence crossover study in healthy Chinese volunteers according to CYP3A5 genotype. A singledose and multiple-dose study were designed. A 96-h pharmacokinetic study followed either tacrolimus or amlodipine dose, and the washout periods between the study phases were 14 days. In the single-dose study, apparent oral clearance (CL/F) of tacrolimus (5 mg) in CYP3A5 expressers was 3.8-fold (p = 0.008) higher than that in CYP3A5 non-expressers. Amlodipine decreased mean tacrolimus CL/F in CYP3A5 expressers by 2.2-fold (p = 0.005), while it had no effect on that in CYP3A5 non-expressers. The CL/F of amlodipine in CYP3A5 non-expressers was 2.0-fold (p = 0.001) higher than that in CYP3A5 expressers. Tacrolimus increased mean amlodipine CL/F in CYP3A5 expressers by 1.4-fold (p = 0.016) while it had no effect on that in CYP3A5 non-expressers. Tacrolimus slightly reduced the AUC 0¨o f amlodipine in both CYP3A5 expressers and non-expressers. Dose adjustment of tacrolimus should be considered according to CYP3A5*3 genetic polymorphism when tacrolimus is coadministered with amlodipine.
Introduction
Kidney transplantation is the most effective means of renal replacement therapy. However, post-transplant hypertension affects 70-90% of all kidney transplant recipients. 1) It has been widely accepted that hypertension remains an independent risk factor for graft loss and reduced life expectancy and a treatment to reduce morbidity and mortality in renal transplant recipients would be of great benefit. 2, 3) Calcium channel blockers are used as the first-line agents for management of hypertension after kidney transplantation. 4) Amlodipine, with a long half-life (35-50 h) , has been shown to provide more stable blood concentration over time to control blood pressure and improve renal function in these patients. 5) Tacrolimus, a calcineurin inhibitor, is a basic component of immunosuppressive therapy in liver and kidney transplant recipients to prevent the rejection of transplanted organs. 6) Tacrolimus has a narrow therapeutic range of 5-20 ng/ml, and wide interindividual pharmacokinetic variability. 7) Tacrolimus, a substrate of CYP3A4, CYP3A5 and P-glycoprotein (P-gp), 8) is mainly metabolized by CYP3A isoenzymes in the liver and intestinal wall. The intrinsic clearance of tacrolimus is approximately 2-fold larger for CYP3A5 than CYP3A4. 9) CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus in kidney transplant recipients. 10, 11) The most extensively studied CYP3A5 SNP involves an A to G transition at position 6986 within intron3 of the CYP3A5 gene (rs776746) leading to an alternative splicing-site of the pre-mRNA. The wild-type allele, designated as CYP3A5*1, produces high levels of full-length CYP3A5 mRNA and expresses high levels of functional CYP3A5 protein (CYP3A5 expression). The variant CYP3A5*3/*3 produces very low or undetectable levels of functional CYP3A5 protein (CYP3A5 nonexpression). Some reports have shown an approximate halving of tacrolimus dose-adjusted trough concentrations and doubling of tacrolimus dose requirements in CYP3A5 expressers compared with CYP3A5 non-expressers. 9) Amlodipine, the substrate of P-gp, 12, 13) is mainly metabolized by CYP3A. 14, 15) There may be drug interactions between tacrolimus and amlodipine when used simultaneously. To date, it is necessary to perform a prospective study to determine the pharmacokinetic interactions between amlodipine and tacrolimus. In this article, we describe our clinical study to evaluate the effect of the CYP3A5*3 allele on the pharmacokinetics of tacrolimus and amlodipine, and drug-drug interactions between them in healthy subjects.
Methods
Subjects: Fifteen healthy male subjects out of 102 unrelated Chinese volunteers genotyped by CYP3A5*3 allele were enrolled in the single-dose study, and 6 out of them for the multiple-dose study ( Table 1 ). All subjects provided written informed consent and were nonsmoking adults and in good health which had been confirmed by medical histories, physical examinations, electrocardiogram and routine clinical-chemical and hematological screenings. This study protocol was approved by the ethics committee of Xiangya Third Hospital, Central South University, Changsha, China.
Study design: A randomized, open-labeled, three-period, crossover clinical pharmacokinetics study was conducted at the Clinical Pharmacology Research Center in Xiangya Third Hospital, Central South University. In each period of the singledose study, subjects received tacrolimus 5 mg (one 1 mg tacrolimus capsule; Astellas Pharma Ireland, Dublin, Ireland), amlodipine 5 mg (one 5 mg amlodipine tablet; Pfizer, Dalian, China), and tacrolimus 5 mg plus amlodipine 5 mg, with a 14-day washout period after each drug period. In each period of the multiple-dose study, subjects received tacrolimus 2 mg bid for 7 days, amlodipine 5 mg qd for 7 days, and tacrolimus 2 mg bid plus amlodipine 5 mg qd for 7 days with a 14-day washout period after each drug period. All participants fasted 12 h before the trial without limiting water and abstained from water 1 h prior to drug administration. Venous blood samples (5 ml) for drug level measurements were collected at 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 24, 48, 72 , and 96 h after dosing in the single-dose study and after dosing of the 7-day treatment in the multiple-dose study. In order to assess whether the steady-state was reached or not, a trough concentration blood sample was collected on day 6 of dosing in the multiple-dose study. All blood samples were centrifuged at 4,000 rpm with a lowtemperature centrifuge for 10 min. The plasma was then separated and stored at ¹80°C until analysis.
Analytical methods: Tacrolimus Blood tacrolimus concentration were measured using a liquid chromatograph coupled to a tandem mass spectrometer (LC-MS/ MS) consisting of an Agilent 6410B triple-quadrupole tandem mass. Detection was performed by positive ion electrospray ionization (ESI) in multiple reaction monitoring (MRM) mode, monitoring the transitions m/z 821.5¼m/z 768.4 and m/z 748.5¼m/z 590.4, for quantification of tacrolimus and IS (clarithromycin), respectively.
After treatment of whole blood tacrolimus samples, 5 µl of supernatant fluid was injected into the LC-MS/MS system. Tacrolimus and the internal standard were separated using a HyPURIYTY C18 chromatographic column (2.1 © 150 mm, 5 µm, Thermo Fisher, Olten, Switzerland) and a Gemini C18 precolumn (4 © 3.0 mm, Phenomenex, Torrance, CA). The mobile phase containing 20 mM ammonium formate with 0.2% formic acid-methanol (10:90, v/v) was used at a flow rate of 0.2 ml/min. The standard calibration curves showed good linearity within the range of 0.2033 to 992.7 µg/l (r 2 = 0.9984). The lower limit of quantitation (LLOQ) was 0.2033 µg/l. The within-day and between-day coefficients of variation of all assays were less than 10%.
Amlodipine
Plasma amlodipine concentrations were measured using an LC-MS/MS apparatus consisting of a API 4000 triple-quadrupole tandem mass. Detection was performed by ESI+ in MRM mode, monitoring the transitions m/z 409¼m/z 238 and m/z 361¼m/z 315, for quantification of amlodipine and IS (nitrendipine), respectively.
After being purified by liquid-liquid extraction without illumination during sample processing, a 10 µl amlodipine sample was injected into the LC-MS/MS system. Amlodipine and IS were separated using a Phenomenex luna C18 chromatographic column (2.0 © 150 mm, 5 µm). The mobile phase containing 5 mM ammonium formate with 1% formic acid-acetonitrile (20:80; v/v) was used at a flow rate of 0.3 ml/min. The standard calibration curves showed good linearity within the range of 0.0732 to 9.365 µg/l (r 2 = 0.9986). The LLOQ was 0.0732 µg/l. The within-day and between-day coefficients of variation of all assays were less than 15%.
Pharmacokinetics analysis: Pharmacokinetic parameters for tacrolimus and amlodipine were estimated using non-compartmental analysis. C max of tacrolimus and amlodipine, and the time to reach peak plasma concentration (t max ) were obtained from the observed individual concentration-time data. The terminal elimination rate constant (k) was estimated by linear regression of the terminal portion of the concentration-time curve, and the t 1/2 was calculated as 0.693/k. The AUCs of tacrolimus and amlodipine were calculated by the trapezoidal rule. The CL/F was calculated as dose/AUC 0-¨. Statistical analysis: All values are expressed as mean « standard deviation (SD). Between different genotypes, t 1/2 and t max were compared with the two-independent-samples Wilcoxon's signed rank test, and other parameters were compared with the two-independent-samples t-test if they showed homogeneity of variance after being natural logarithm-transformed, or compared with the two-independent-samples Wilcoxon's signed rank test if they showed heterogeneity of variance. A 2-tailed p value was used, and the level of statistical significance was set at p < 0.05. The point estimate and 90% confidence intervals (CI) for the ratios (dividing the AUC of tacrolimus with amlodipine ingestion by each without-amlodipine ingestion) of natural log-normalized tacrolimus pharmacokinetic parameters (C max and AUC) were calculated. No clinically significant differences in C max or AUC between tacrolimus alone and tacrolimus plus amlodipine were considered if the 90% CI of the logarithm-transformed ratios of them were within the predefined range of 0.80 to 1.25.
All statistical analyses were performed using SPSS version 13.0 (SPSS, Inc., Chicago, IL).
Results
The genotypic frequencies of CYP3A5*1/*1, *1*/*3 and *3/*3 were 6.9% (n = 7), 40.2% (n = 41), and 52.9% (n = 54), respectively, in the prestudy population. The allelic frequency of CYP3A5*3 was 0.7, which is similar to that observed in Japanese (0.77, n = 400), but lower than in Caucasian (0.85, n = 54) subjects.
16) The distribution of genotypes was consistent with the Hardy-Weinberg equilibrium (p > 0.05, chi-square test). None of the demographic characteristics was significantly different by CYP3A5 genotype ( Table 1) .
Effect of amlodipine on the pharmacokinetics of tacrolimus in relation to CYP3A5 genetic polymorphism: Effect of CYP3A5 genotype on tacrolimus during the different phases After administration of a single 5 mg oral dose of tacrolimus alone, apparent oral clearance (CL/F) of tacrolimus in CYP3A5 expressers was 3.8-fold (p = 0.008) higher than that in CYP3A5 non-expressers. The AUC 0-¨a nd CL/F of tacrolimus in CYP3A5 non-expressers were 2.7-(p = 0.008) and 0.27-(p = 0.008) fold more than in CYP3A5 expressers. After administration of 2 mg twice-daily oral doses of tacrolimus for 7 days, the AUC 0-¨a nd C max of tacrolimus were 9.81-fold and 10.62-fold larger in subjects with the CYP3A5*3/*3 genotype than in CYP3A5 expressers, respectively ( Table 2) . Effect of amlodipine on tacrolimus pharmacokinetics in the singledose administration study Amlodipine decreased the CL/F of tacrolimus in CYP3A5 expressers by 2.2-fold (p = 0.005), while it had no effect on that in CYP3A5 non-expressers (p = 0.921). It significantly increased the mean AUC 0-¨o f tacrolimus 2.44-fold (range 1.2-4.8) only in the participants with the CYP3A5 genotype (p = 0.005). However, amlodipine had no significant effect on the mean C max or t 1/2 of tacrolimus in any of the genotype groups (Table 2, Figs. 1a and 1b). Effect of amlodipine on tacrolimus pharmacokinetics in the multiple-dose administration study
When tacrolimus was administered in combination with amlodipine for 7 days, the mean AUC 0-¨a nd C max of tacrolimus were raised 4.1-fold and 5.3-fold in subjects with the CYP3A5*1/ *3 genotype, respectively, while they were decreased 0.55-fold and 0.58-fold in those with the CYP3A5*3/*3 genotype, respectively ( Table 2, Figs. 1c and 1d) .
Effect of tacrolimus on the pharmacokinetics of amlodipine in relation to CYP3A5 genetic polymorphism: Effect of CYP3A5 genotype on amlodipine during the different phases After administration of a single 5 mg oral dose of amlodipine alone, the CL/F of amlodipine in CYP3A5 non-expressers was 2.0-fold (p = 0.001) higher than that in CYP3A5 expressers. The AUC 0-¨a nd CL/F of amlodipine in CYP3A5 expressers were 2.2 (p = 0.001) and 0.50 (p = 0.001) times more than in CYP3A5 non-expressers. After administration of 5 mg once-daily oral doses of amlodipine for 7 days, the AUC 0-¨a nd C max of amlodipine in CYP3A5 non-expressers were 1.7-fold and 1.6-fold larger than those in CYP3A5 expressers, respectively ( Table 3) . Effect of tacrolimus on amlodipine pharmacokinetics in the singledose administration study Tacrolimus increased the CL/F of amlodipine 1.49-fold in the participants with the CYP3A5 genotype (p = 0.016) while it had no effect on that in CYP3A5 non-expressers (p = 0.099). It significantly decreased the mean AUC 0-¨o f amlodipine 0.74-fold in the participants with the CYP3A5 expression (p = 0.016) ( Table 3 , Figs. 2a and 2b) . Tacrolimus had no significant effect on the mean C max or t 1/2 of amlodipine in any of the genotype groups. The effect of tacrolimus on the concentration-time profiles of amlodipine were significant and resulted in a decrease in amlodipine concentration only in the CYP3A5 expressers. Effect of tacrolimus on amlodipine pharmacokinetics in the multiple-dose administration study When tacrolimus was administered in combination with amlodipine after 7 days, the mean AUC 0-¨a nd C max of amlodipine were reduced 0.84-fold and 0.97-fold in subjects with the CYP3A5*1/*3 genotype, respectively, while they were decreased 0.70-fold and 0.81-fold in those with the CYP3A5*3/*3 genotype, respectively ( Table 3, Figs. 2c and 2d) .
Discussion
In the present study, we found that there were significant pharmacokinetic interactions between tacrolimus and amlodipine in relation to CYP3A5*3 polymorphism.
Our study showed that CYP3A5 genotype had an important effect on the pharmacokinetics of tacrolimus in vivo and this role would become more obvious in multiple-dose administration than in single-dose administration. This result is in line with the review article.
17) CYP3A5*1 carriers, from all ethnic groups but African, have around 1.5-2 fold lower blood concentrations for a given dose of tacrolimus than CYP3A5*3/*3 homozygous subjects. 18) For CYP3A5 expressers, amlodipine decreased the CL/F and increased the AUC of tacrolimus in both the single-dose and multiple-dose study. In vitro data have indicated that CYP3A5 expressers had higher metabolic activity toward CYP3A substrates than CYP3A4. 19) Our in vivo study was consistent with this result and showed that amlodipine had a significant inhibition on CYP3A5 activity and led to a rise in the AUC of tacrolimus in combination with amlodipine compared with tacrolimus alone in CYP3A5 expressers. Clinical findings showed that calcium channel blockers such as diltiazem, 20, 21) felodipine, 22) nifedipine 23) and nicardipine 24, 25) had significant impact on the pharmacokinetics of tacrolimus via inhibition of CYP3A4 or P-gp. Toupance et al. 26) demonstrated that, in hypertensive renal transplant recipients, amlodipine would not interfere with the distribution and metabolism of CsA, a CYP3A4 and P-gp substrate. However, two other clinical studies 12, 13) have shown that amlodipine increased the absorption of CsA and led to an average 40% increase of CsA levels above baseline. Thus, amlodipine may raise the CsA bioavailability via inhibition of P-gp.
Tacrolimus is a substrate of P-gp product of MDR1 gene, 16, 27, 28) but it still remains controversial whether the MDR1 SNPs affect tacrolimus pharmacokinetics. 29, 30) Our study did not find any significant difference in tacrolimus pharmacokinetic parameters among different MDR1 genotypes. The transport of [ 3 H]daunorubicin, a P-gp substrate, was strongly inhibited by amlodipine with IC50 values of 22.0 µm. 31) By contrast, the C max of amlodipine in this study was far less than 22.0 µm, suggesting it is impossible for amlodipine in such a concentration to inhibit intestinal P-gp. In the present study, there was no difference in the elimination half life (t 1/2 ) of tacrolimus treatment with amlodipine and withdrawal of it in CYP3A5 expressers, suggesting that amlodipine mainly inhibits CYP3A5 in the intestine not CYP3A4 in the liver.
However, for CYP3A5 nonexpressers, the single-dose study suggested that amlodipine had no effect on the CL/F of tacrolimus, while it decreased the AUC of tacrolimus in the multiple-dose investigation. Yong Chung et al. 32) have suggested that intrapatient variability of tacrolimus clearance is correlated with CYP3A5 Fig. 1 . Mean concentration-time curves of tacrolimus in healthy subjects with CYP3A5 (a)*1/*1 or *1/*3 genotype (n = 9), (b)*3/*3 genotype (n = 6) after a single 5 mg oral dose of tacrolimus alone or with a 5 mg oral dose of amlodipine, CYP3A5 (c)*1/*3 genotype (n = 3), (d)*3/*3 genotype (n = 3) after 2 mg twice-daily oral doses of tacrolimus for 7 days alone or with 5 mg once-daily oral doses of amlodipine for 7 days Arithmetic mean « SD are presented. CYP3A5*3, Tacrolimus and Amlodipinegenotype. In healthy individuals taking tacrolimus as part of a bioequivalence study, CYP3A5 expressers had less intrapatient variability as compared with CYP3A5 non-expressers. This observation was explained by the fact that in patients without functional CYP3A5 enzyme, the metabolism of tacrolimus depends exclusively on the activity of CYP3A4. Because the CYP3A4 enzyme is more sensitive to induction and inhibition, CYP3A5 non-expressers could be more prone to variable tacrolimus clearance over time.
CYP3A4*1B, related to tacrolimus metabolism, was limited in Chinese subjects because of its low mutation frequency in Asian populations. 33, 34) CYP3A4*18B, which is actually called CYP3A4*1G 35) because the last variant contains a Leu293Pro change and the 20230 G>A substitution, has the highest mutation frequency in the Chinese population. The CYP3A4*1G mutation allele has higher activity than the CYP3A4*1/*1 wild type.
27) It has been identified that CYP3A4*1G polymorphism was associated with the pharmacokinetics of tacrolimus. 35, 36) In our study, CL/F of tacrolimus (5 mg) in CYP3A4*1/*1 genotype subjects (98.5 l/h) was less than that in CYP3A4*1G carriers (162.4 l/h) (p = 0.556) in the single-dose study. The result was in accordance with the above report 36) but amlodipine did not significantly affect tacrolimus pharmacokinetics based on CYP3A4*1G ( Table 4) .
It may be postulated that amlodipine has greater impact on CYP3A5*1 carriers than the CYP3A4*1G allele. There may exist some other factors influencing the disposition of tacrolimus for subjects with CYP3A5 nonexpression. An in vivo study identified both CYP3A4 and CYP3A5 as important determinants of tacrolimus disposition.
37) The CYP3A5*1 allele may be in linkage disequilibrium with the CYP3A4*1B allele. 38) However, there is no evidence about linkage for the CYP3A5*1 allele and CYP3A4*1G.
At present, there are only two cases of interactions between amlodipine and tacrolimus reported by Leroy et al. 39) and Zhao et al. 40) Both child renal transplant patients with CYP3A5*3/*3 suffered from nephrotoxity related to a raised blood level of tacrolimus in a situation of coadministration with amlodipine. But our study indicated that amlodipine reduced the AUC of tacrolimus in three subjects with CYP3A5*3/*3 genotypes in the multipledose group, which was not consistent with the above reports. 39, 40) This result could partly be explained by genetic variants between the Caucasian and Asian races. The former, Caucasian boys, might be CYP3A4*1B expressers, and the latter healthy Asian subjects in the present study have CYP3A4*1G alleles. In our study, some interactions of CYP3A4/5 SNPs could be observed that need further investigation in larger sample sizes. Comparison between the *1/*1G + *1G/*1G and *1/*1 groups when tacrolimus alone administrated.
b
Comparison between tacrolimus alone and tacrolimus plus amlodipine in the *1/*1G + *1G/*1G groups. Amlodipine is primarily metabolized by CYP3A4. 14, 15) Telaprevir, a potent inhibitor of CYP3A4, significantly inhibited the metabolism of amlodipine, 41) as is also known to occur in ritonavir and indinavir. 42) However, there are some data to reveal the role of CYP3A5 in the pharmacokinetics of amlodipine in humans. 43, 44) Because CYP3A4 and CYP3A5 have similar catalytic specificities, the relative contribution of these two enzymes on the disposition of amlodipine is yet unclear. Evidence shows that grapefruit juice 45) and diltiazem, 46) both CYP3A and P-gp substrates, affect the disposition of amlodipine.
The present findings showed the AUC 0-¨o f amlodipine in CYP3A5 non-expressers was lower than that in CYP3A5 expressers in the single-dose study, which is consistent with Kim's study. 43) There may exist other metabolic enzymes or transporters in the intestine affecting the absorption of amlodipine. However, the result of amlodipine AUC 0-¨i n the multiple-dose study was opposite that in the single-dose study, suggesting CYP3A5 is the key influential factor in the elimination of amlodipine. Tacrolimus increased the CL/F of amlodipine in CYP3A5 expressers while it had no effect on that in CYP3A5 non-expressers in the single-dose study. In contrast, in the multiple-dose study, tacrolimus reduced the AUC 0-ö f amlodipine in both CYP3A5 expressers and non-expressers. The minimum inhibitory concentration of tacrolimus on CYP3A4 and CYP3A5 was 15 µM, which is much greater than the therapeutic concentration of tacrolimus. 47, 48) However, there exists limited evidence showing the CYP enzymes and P-gp induction of tacrolimus. Iwasaki et al. 49) reported that when SpragueDawley male rats were pretreated with tacrolimus (0.4, 2 or 10 mg/kg/d) for 7 days, the microsomal content of total cytochrome P-450 in the liver was increased to 126-130% of control levels. In addition, Hauser et al. 50) showed that the induction of P-gp expression in HAEC and RPTC under conditions of tacrolimus (0.01 to 0.2 µM up to 7 days) did not appear, while P-gp expression was raised to higher concentrations with 0.6 to 1.2 µM. Therefore, tacrolimus may protect the cells from exposure to toxic concentrations of the drugs via inducing the expression of CYP3A4 or CYP3A5 or P-gp in the gut. The reduced amlodipine levels caused by tacrolimus in the multiple-dose study might be explained by the induction of tacrolimus. This induction leads to the similar AUC 0-¨o f tacrolimus in CYP3A5 expressers between the multipledose study and the single-dose study. Because the enzyme induction is a slow time-dependent regulatory process, 51) the reduction in amlodipine concentration in the single-dose study cannot be attributed to the enzyme induction by tacrolimus and there might be other reasons for amlodipine plasma concentration reduction. We still need further research to clarify this.
Based on the above effects of CYP3A5 genotypes and amlodipine on the pharmacokinetics of tacrolimus, the dosage of tacrolimus in CYP3A5 expressers should be greater than that in CYP3A5 nonexpressers to achieve the same tacrolimus concentration. If tacrolimus is coadministered with amlodipine in CYP3A5 expressers, the dosage of tacrolimus should be reduced accordingly.
In summary, the CYP3A5*3 allele is the main determinant of the CL/F of tacrolimus and amlodipine and there are significant pharmacokinetic interactions between tacrolimus and amlodipine according to CYP3A5 genotypes. Amlodipine significantly increased tacrolimus blood exposure in CYP3A5*1 carriers and decreased it in CYP3A5*3 mutant homozygotes. Dose adjustment of tacrolimus should be considered according to CYP3A5*3 genetic polymorphism when tacrolimus is coadministered with amlodipine. Fig. 2 . Mean concentration-time curves of amlodipine in healthy subjects with CYP3A5 (a)*1/*1 or *1/*3 genotype (n = 9), (b)*3/*3 genotype (n = 6) after a single 5 mg oral dose of amlodipine alone or with a 5 mg oral dose of tacrolimus, CYP3A5 (c)*1/*3 genotype (n = 3), (d)*3/*3 genotype (n = 3) after 5 mg once-daily oral doses of amlodipine for 7 days alone or with 2 mg twice-daily oral doses of tacrolimus for 7 days Arithmetic mean « SD are presented.
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